Literature DB >> 3688278

Neuroleptic responsivity of negative and positive symptoms in schizophrenia.

A Breier1, O M Wolkowitz, A R Doran, A Roy, J Boronow, D W Hommer, D Pickar.   

Abstract

The authors prospectively examined the effects of double-blind, placebo-controlled neuroleptic withdrawal and administration on ratings of negative and positive symptoms in 19 young patients with chronic schizophrenia. Negative symptoms were significantly reduced by neuroleptic treatment, and negative and positive symptoms demonstrated similar patterns of reduction and exacerbation during neuroleptic treatment and withdrawal, respectively. The changes in negative and positive symptoms induced by neuroleptic treatment and withdrawal were not significantly correlated, however. The negative and positive symptom profiles of individual patients were significantly altered by neuroleptic treatment, indicating limitations to the cross-sectional classification of patients on the basis of predominance of one or the other symptom group. The authors discuss implications for the neurobiological underpinnings of negative and positive symptoms.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3688278     DOI: 10.1176/ajp.144.12.1549

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  10 in total

1.  Antipsychotics and amotivation.

Authors:  Gagan Fervaha; Hiroyoshi Takeuchi; Jimmy Lee; George Foussias; Paul J Fletcher; Ofer Agid; Gary Remington
Journal:  Neuropsychopharmacology       Date:  2015-01-08       Impact factor: 7.853

2.  Facts and meaning in psychiatry. An anthropological approach to the lifeworld of schizophrenics.

Authors:  E E Corin
Journal:  Cult Med Psychiatry       Date:  1990-06

3.  Lack of association between dopaminergic antagonism and negative symptoms in schizophrenia: a positron emission tomography dopamine D2/3 receptor occupancy study.

Authors:  Gagan Fervaha; Fernando Caravaggio; David C Mamo; Benoit H Mulsant; Bruce G Pollock; Shinichiro Nakajima; Philip Gerretsen; Tarek K Rajji; Wanna Mar; Yusuke Iwata; Eric Plitman; Jun Ku Chung; Gary Remington; Ariel Graff-Guerrero
Journal:  Psychopharmacology (Berl)       Date:  2016-08-24       Impact factor: 4.530

Review 4.  The "two-headed" latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment.

Authors:  Ina Weiner
Journal:  Psychopharmacology (Berl)       Date:  2003-02-25       Impact factor: 4.530

Review 5.  Fluphenazine (oral) versus placebo for schizophrenia.

Authors:  Hosam E Matar; Muhammad Qutayba Almerie; Stephanie Sampson
Journal:  Cochrane Database Syst Rev       Date:  2013-07-17

Review 6.  A clinical guide to antipsychotic drugs.

Authors:  J T Schwartz; A W Brotman
Journal:  Drugs       Date:  1992-12       Impact factor: 9.546

7.  Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors.

Authors:  J E Leysen; P M Janssen; A Schotte; W H Luyten; A A Megens
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

Review 8.  Adverse effects of antipsychotic agents. Do newer agents offer advantages?

Authors:  D G Owens
Journal:  Drugs       Date:  1996-06       Impact factor: 9.546

9.  Efficacy of amisulpride and olanzapine for negative symptoms and cognitive impairments: An open-label clinical study.

Authors:  Subodh Kumar; Suprakash Chaudhury
Journal:  Ind Psychiatry J       Date:  2014-01

Review 10.  Fluphenazine (oral) versus placebo for schizophrenia.

Authors:  Hosam E Matar; Muhammad Qutayba Almerie; Stephanie J Sampson
Journal:  Cochrane Database Syst Rev       Date:  2018-06-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.